QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
